BioAtla is a clinical-stage biopharmaceutical company developing its antibody-based therapeutics for the treatment of solid tumor cancer. Co.'s conditionally active biologics (CAB) capitalize on its proprietary discoveries with respect to tumor biology, enabling Co. to target known and validated tumor antigens. Co.'s CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy tissue. The applicability of Co.'s CAB technology allows Co. to develop a range of product candidate modalities, such as monoclonal antibodies, antibody-drug conjugates, T cell-engaging bispecific antibodies and chimeric antigen receptor T cells. The BCAB stock yearly return is shown above.
The yearly return on the BCAB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BCAB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|